Non‐invasive models for predicting histology in patients with chronic hepatitis B

Abstract

Models with non-invasive markers in predicting histology from CHC patients were unsuitable for CHB patients. No variables consisting of simple and readily available markers were able to predict cirrhosis accurately in patients with CHB.

Retrospective Evaluation of Serum Markers APRI and AST/ALT for Assessing Liver Fibrosis and Cirrhosis in Chronic Hepatitis B and C Patients with Hepatocellular Carcinoma

“…Co mp a r i s o n o f No n i n v a s i v e S e r u m Ma r k e r s a mo n g Di f f e r e n t S t a g e s o f L i v e r F i b r o s (12). Recently, the pathogenesis of liver fibrosis in CHB was suggested to be different from that of CHC (13) (20). In addition, ALT is associated with sex and body mass index (20,21 …”

“…APRI, AST/ALT, platelets, AST, albumin, total bilirubin and alkaline phosphatase which are well-known predictors of advanced liver diseases (9)(10)(11)(12)(13)(14)(15) (9). In this study, the cutoff values of APRI were set at 0.…”

“…(9). APRI has been used in the evaluation of patients with alcoholic liver fibrosis, CHB, and CHC (9)(10)(11)(12)(13) T a b l e 1 . Cl i n i c a l Ch a r a c t e r i s t i c s o f Ch r o n i c He p a t i t i s P a t i e n t s i n T h i s S t u d (Fig.…”

Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C–related fibrosis: A systematic review

“…The APRI has been examined in hepatitis B, but the few published studies suggest reduced accuracy. 76,77 Therefore, to avoid introducing further heterogeneity, we restricted our analysis to HCV. Ideally, we would have also examined other test characteristics such as cost-effectiveness and impact on clinical outcomes.…”

Karaciğer Fibrozisinin İnvazif Olmayan Dolaylı Biyokimyasal Belirteçleri

“…Son yaklaşımlarda birden fazla biyokimyasal belirtecin kombine edilmesinin [36][37][38][39][40] bu hastalardaki tanısal doğruluğu arttıracağı ileri sürülmüştür. Ayrıca, yapılan çalışmalar incelendiğinde siroz hastalarında dolaylı biyokimyasal belirteçlerin daha iyi bir performansa sahip olduğu dikkatimizi çekmiştir 20,25,37,[40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59] . Son yıllarda yapılan çalışmalarda karaciğer biyopsisinden önce biyokimyasal testlerin ve indekslerin birinci basamak tarama testi olarak kullanılmasının özellikle belirgin fibrozis ve sirozun tespiti ve dışlanmasında doğru yol gösterici olup gereksiz karaciğer biyopsisi yapılmasını önleyebileceği vurgulanmıştır.…”